Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity

Platelets

Volumn 27, Issue 5, 2016, Pages 446-451

  Gross, Lisa ^a   Sibbing, Dirk ^a,b   Eickhoff, Madeleine ^a   Baquet, Moritz ^a   Orban, Martin ^a   Krieg, Anne ^a   Grujic, Katarina ^a   Theiss, Hans D ^a   Brunner, Stefan ^a   Teupser, Daniel ^c   Holdt, Lesca ^c   Massberg, Steffen ^a,b   Mehilli, Julinda ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Bioresorbable vascular scaffold; platelet activation; platelet function testing; scaffold thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; HEPARIN; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ADULT; ANALYZER; ARTICLE; BIORESORBABLE SCAFFOLD; CORONARY ARTERY DISEASE; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCAFFOLD THROMBOSIS; SURFACE AREA; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; AGED; BIODEGRADABLE IMPLANT; BLOOD; CARDIOVASCULAR DISEASES; DRUG EFFECTS; METABOLISM; MIDDLE AGED; THROMBOCYTE; THROMBOCYTE ACTIVATION; TISSUE SCAFFOLD; TREATMENT OUTCOME;

ABSORBABLE IMPLANTS; AGED; BLOOD PLATELETS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; THROMBOSIS; TISSUE SCAFFOLDS; TREATMENT OUTCOME;

EID: 84961207802     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2016.1143918     Document Type: Article

References (32)

1. P.W.Serruys, Y.Onuma, D.Dudek, P.C.Smits, J.Koolen, B.Chevalier, de Bruyne B, Thuesen L, McClean D, van Geuns RJ, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol 2011;58(15):1578–1588.
2. D.Dudek, Y.Onuma, J.A.Ormiston, L.Thuesen, K.Miquel-Hebert, P.W.Serruys Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention 2012;7(9):1060–1061.
3. Y.Onuma, P.W.Serruys, J.A.Ormiston, E.Regar, M.Webster, L.Thuesen, Dudek D, Veldhof S, Rapoza R. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention 2010;6(4):447–453.
4. A.Mattesini, G.G.Secco, G.Dall’Ara, M.Ghione, J.C.Rama-Merchan, A.Lupi, Viceconte N, Lindsay AC, De Silva R, Foin N, et al. ABSORB biodegradable stents versus second-generation metal stents: A comparison study of 100 complex lesions treated under OCT guidance. JACC Cardiovasc Interv 2014;7(7):741–750.
5. P.W.Serruys, H.M.Garcia-Garcia, Y.Onuma From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33(1):16–25b.
6. D.Capodanno, T.Gori, H.Nef, A.Latib, J.Mehilli, M.Lesiak, G.Caramanno, C.Naber, C.Di Mario, A.Colombo, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015;10(10):1144–53. doi:10.4244/EIJY14M07_11.
7. I.Iakovou, T.Schmidt, E.Bonizzoni, L.Ge, G.M.Sangiorgi, G.Stankovic, Airoldi F, Chieffo A, Montorfano M, Carlino M, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293(17):2126–2130.
8. R.Moreno, C.Fernandez, R.Hernandez, F.Alfonso, D.J.Angiolillo, M.Sabate, Escaned J, Bañuelos C, Fernández-Ortiz A, Macaya C. Drug-eluting stent thrombosis: Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45(6):954–959.
9. K.Kolandaivelu, R.Swaminathan, W.J.Gibson, V.B.Kolachalama, K.L.Nguyen-Ehrenreich, V.L.Giddings, Coleman L, Wong GK, Edelman ER. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123(13):1400–1409.
10. W.J.van der Giessen, A.M.Lincoff, R.S.Schwartz, H.M.van Beusekom, P.W.Serruys, H.D.R.JrHolmes DR, Ellis SG, Topol EJ. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94(7):1690–1697.
11. K.C.Koskinas, Y.S.Chatzizisis, A.P.Antoniadis, G.D.Giannoglou Role of endothelial shear stress in stent restenosis and thrombosis: Pathophysiologic mechanisms and implications for clinical translation. J Am Coll Cardiol 2012;59(15):1337–1349.
12. U.S.Tantry, L.Bonello, D.Aradi, M.J.Price, Y.H.Jeong, D.J.Angiolillo, Stone GW, Curzen N, Geisler T, Ten Berg J, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013;62(24):2261–2273.
13. L.Bonello, U.S.Tantry, R.Marcucci, R.Blindt, D.J.Angiolillo, R.Becker, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56(12):919–933.
14. D.Aradi, R.F.Storey, A.Komocsi, D.Trenk, D.Gulba, R.G.Kiss, Husted S, Bonello L, Sibbing D, Collet JP, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2014;35(4):209–215.
15. D.Sibbing, S.Braun, T.Morath, J.Mehilli, W.Vogt, A.Schomig, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53(10):849–856.
16. D.Aradi, A.Tornyos, T.Pinter, A.Vorobcsuk, A.Konyi, J.Falukozy, Veress G, Magyari B, Horváth IG, Komócsi A. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: Impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 2014;63(11):1061–1070.
17. C.Viviani Anselmi, C.Briguori, R.Roncarati, L.Papa, G.Visconti, A.Focaccio, De Micco F, Latronico MV, Pagnotta P, Condorelli G. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv 2013;6(11):1166–1175.
18. L.B.Balsam, A.J.Wagers, J.L.Christensen, T.Kofidis, I.L.Weissman, R.C.Robbins Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature 2004;428(6983):668–673.
19. F.Mangiacapra, J.Bartunek, N.Bijnens, A.J.Peace, K.Dierickx, E.Bailleul, Di Serafino L, Pyxaras SA, Fraeyman A, Meeus P, et al. Periprocedural variations of platelet reactivity during elective percutaneous coronary intervention. J Thromb Haemost 2012;10(12):2452–2461.
20. T.Palmerini, G.Biondi-Zoccai, D.Della Riva, A.Mariani, P.Genereux, A.Branzi, Stone GW. Stent thrombosis with drug-eluting stents: Is the paradigm shifting? J Am Coll Cardiol 2013;62(21):1915–1921.
21. Y.Ishibashi, Y.Onuma, T.Muramatsu, S.Nakatani, J.Iqbal, G.-G.HMGarcia-Garcia, Bartorelli AL, Whitbourn R, Abizaid A, Serruys PW. Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial. EuroIntervention 2014;10(4):449–57. doi:10.4244/EIJV10I4A78.
22. W.Hochholzer, D.Trenk, H.P.Bestehorn, B.Fischer, C.M.Valina, M.Ferenc, Gick M, Caputo A, Büttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006;48(9):1742–1750.
23. K.Gutensohn, C.Beythien, J.Bau, T.Fenner, P.Grewe, R.Koester, Padmanaban K, Kuehnl P. In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 2000;99(6):577–585.
24. C.Beythien, K.Gutensohn, J.Bau, C.W.Hamm, P.Kuhnl, T.Meinertz, Terres W. Influence of stent length and heparin coating on platelet activation: A flow cytometric analysis in a pulsed floating model. Thromb Res 1999;94(2):79–86.
25. C.V.Bourantas, M.I.Papafaklis, H.M.Garcia-Garcia, V.Farooq, R.Diletti, T.Muramatsu, Zhang Y, Kalatzis FG, Naka KK, Fotiadis DI, et al. Short- and long-term implications of a bioresorbable vascular scaffold implantation on the local endothelial shear stress patterns. JACC Cardiovasc Interv 2014;7(1):100–101.
26. C.V.Bourantas, M.I.Papafaklis, A.Kotsia, V.Farooq, T.Muramatsu, J.Gomez-Lara, Zhang YJ, Iqbal J, Kalatzis FG, Naka KK, et al. Effect of the endothelial shear stress patterns on neointimal proliferation following drug-eluting bioresorbable vascular scaffold implantation: An optical coherence tomography study. JACC Cardiovasc Interv 2014;7(3):315–324.
27. P.A.Gurbel, K.P.Bliden Platelet activation after stenting with heparin-coated versus noncoated stents. Am Heart J 2003;146(4):E10.
28. A.Kastrati, J.Mehilli, J.Dirschinger, F.Dotzer, H.Schuhlen, F.J.Neumann, Fleckenstein M, Pfafferott C, Seyfarth M, Schömig A. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103(23):2816–2821.
29. J.Pache, A.Kastrati, J.Mehilli, H.Schuhlen, F.Dotzer, J.Hausleiter, Fleckenstein M, Neumann FJ, Sattelberger U, Schmitt C, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003;41(8):1283–1288.
30. G.W.Stone, A.Rizvi, W.Newman, K.Mastali, J.C.Wang, R.Caputo, Doostzadeh J, Cao S, Simonton CA, Sudhir K, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362(18):1663–1674.
31. E.Kedhi, K.S.Joesoef, E.McFadden, J.Wassing, C.van Mieghem, D.Goedhart, Smits PC. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial. Lancet 2010;375(9710):201–209.
32. P.W.Serruys, B.Chevalier, D.Dudek, A.Cequier, D.Carrie, A.Iniguez, Dominici M, van der Schaaf RJ, Haude M, Wasungu L, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015 Jan 3;385(9962):43–54. doi:10.1016/S0140-6736(14)61455-0. Epub 2014 Sep 14.